Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease

NCT00602680 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Insufficient expected benefit risk

Conditions

Alzheimer's Disease

Interventions

DRUG: SSR180711C
DRUG: donepezil
DRUG: placebo

Sponsor

Sanofi